

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Steve Pakola et al.	Confirmation No.:	3082
Application No.:	10/729,475	Art Unit:	1651
Filed:	December 5, 2003	Examiner:	T. Kim
Title:	PHARMACOLOGICAL VITREOLYSIS		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


STATEMENT REGARDING CHANGE IN ASSIGNEE NAME

Dear Madam:

In response to the Notice of Allowance mailed December 17, 2008, Applicants are submitting herewith authorization for the payment of the issue fees. Applicants have listed the name of the assignee on the enclosed Form PTOL-85 as "ThromboGenics NV". On October 29, 2003, at Reel 15189, Frame 941, an assignment from the inventors to "Thromb-X NV" was recorded. The documents reflecting the corporate name change from "Thromb-X NV" to "ThromboGenics NV" have been filed with the USPTO today, February 9, 2009, for recordation. Accordingly, Applicants respectfully request the patent issue in the name of "ThromboGenics NV".

Dated: 9 February 2009

Respectfully submitted,



Rolando Medina, Ph.D.  
Registration No.: 54,756  
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109  
(617) 526-6000 (telephone)  
(617) 526-5000 (facsimile)